500 related articles for article (PubMed ID: 33726698)
21. Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma.
Chen QF; Li W; Wu PH; Shen LJ; Huang ZL
World J Gastroenterol; 2019 Sep; 25(35):5266-5282. PubMed ID: 31558872
[TBL] [Abstract][Full Text] [Related]
22. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma.
Dai Y; Qiang W; Lin K; Gui Y; Lan X; Wang D
Cancer Immunol Immunother; 2021 Apr; 70(4):967-979. PubMed ID: 33089373
[TBL] [Abstract][Full Text] [Related]
23. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
24. Prognostic implications of aberrantly expressed methylation‑driven genes in hepatocellular carcinoma: A study based on The Cancer Genome Atlas.
Li J; Chen N; Gong X
Mol Med Rep; 2019 Dec; 20(6):5304-5314. PubMed ID: 31661127
[TBL] [Abstract][Full Text] [Related]
25. AKR1B10 expression characteristics in hepatocellular carcinoma and its correlation with clinicopathological features and immune microenvironment.
Ma LN; Ma Y; Luo X; Ma ZM; Ma LN; Ding XC
Sci Rep; 2024 May; 14(1):12149. PubMed ID: 38802416
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of epithelial mesenchymal transition-related prognostic model for hepatocellular carcinoma.
Wang X; Xing Z; Xu H; Yang H; Xing T
Aging (Albany NY); 2021 Apr; 13(10):13822-13845. PubMed ID: 33929972
[TBL] [Abstract][Full Text] [Related]
27. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.
Yu S; Cai L; Liu C; Gu R; Cai L; Zhuo L
Mol Med; 2021 Apr; 27(1):36. PubMed ID: 33832428
[TBL] [Abstract][Full Text] [Related]
28. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature.
Zhao K; Xu L; Li F; Ao J; Jiang G; Shi R; Chen F; Luo Q
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32789471
[TBL] [Abstract][Full Text] [Related]
29. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.
Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y
Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539
[TBL] [Abstract][Full Text] [Related]
30. Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma.
Dai K; Liu C; Guan G; Cai J; Wu L
BMC Cancer; 2022 May; 22(1):496. PubMed ID: 35513781
[TBL] [Abstract][Full Text] [Related]
31. The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma.
Deng M; Sun S; Zhao R; Guan R; Zhang Z; Li S; Wei W; Guo R
Mol Med; 2022 Feb; 28(1):16. PubMed ID: 35123387
[TBL] [Abstract][Full Text] [Related]
32. A gene-based risk score model for predicting recurrence-free survival in patients with hepatocellular carcinoma.
Wang W; Wang L; Xie X; Yan Y; Li Y; Lu Q
BMC Cancer; 2021 Jan; 21(1):6. PubMed ID: 33402113
[TBL] [Abstract][Full Text] [Related]
33. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma.
Sun XY; Yu SZ; Zhang HP; Li J; Guo WZ; Zhang SJ
Cancer Med; 2020 Apr; 9(8):2868-2878. PubMed ID: 32068352
[TBL] [Abstract][Full Text] [Related]
34. Integrated analysis of methylation-driven genes and pretreatment prognostic factors in patients with hepatocellular carcinoma.
He D; Liao S; Cai L; Huang W; Xie X; You M
BMC Cancer; 2021 May; 21(1):599. PubMed ID: 34034705
[TBL] [Abstract][Full Text] [Related]
35. Identification of prognostic biomarkers associated with the occurrence of portal vein tumor thrombus in hepatocellular carcinoma.
Lin T; Lin Z; Mai P; Zhang E; Peng L
Aging (Albany NY); 2021 Apr; 13(8):11786-11807. PubMed ID: 33878734
[TBL] [Abstract][Full Text] [Related]
36. Seven-senescence-associated gene signature predicts overall survival for Asian patients with hepatocellular carcinoma.
Xiang XH; Yang L; Zhang X; Ma XH; Miao RC; Gu JX; Fu YN; Yao Q; Zhang JY; Liu C; Lin T; Qu K
World J Gastroenterol; 2019 Apr; 25(14):1715-1728. PubMed ID: 31011256
[TBL] [Abstract][Full Text] [Related]
37. Mining prognostic markers of Asian hepatocellular carcinoma patients based on the apoptosis-related genes.
Yan J; Cao J; Chen Z
BMC Cancer; 2021 Feb; 21(1):175. PubMed ID: 33602168
[TBL] [Abstract][Full Text] [Related]
38. Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma.
Zhang Y; Tang Y; Guo C; Li G
Aging (Albany NY); 2021 May; 13(9):12865-12895. PubMed ID: 33946043
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.
Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L
J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766
[TBL] [Abstract][Full Text] [Related]
40. The competitive endogenous RNA regulatory network reveals potential prognostic biomarkers for overall survival in hepatocellular carcinoma.
Zhang Z; Li J; He T; Ouyang Y; Huang Y; Liu Q; Wang P; Ding J
Cancer Sci; 2019 Sep; 110(9):2905-2923. PubMed ID: 31335995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
